Natalie Mount

Natalie Mount is an accomplished professional with extensive experience in the biotechnology and pharmaceutical sectors, currently serving as a Venture Partner at Abingworth and Board Chair at Wugen since August 2022. Natalie holds the position of Independent Board Director at Rinri Therapeutics since January 2020. Previously, Natalie was the Chief Executive Officer of Adaptate Biotherapeutics from its inception until its acquisition by Takeda in June 2022, and served as an Independent Board Director at GenSight Biologics from April 2017 to April 2021. Natalie's earlier roles include Chief Scientific Officer at GammaDelta Therapeutics and Chief Clinical Officer at the Cell and Gene Therapy Catapult, contributing significantly to the advancement of cell-based therapies. Natalie's career also includes leadership positions at Pfizer, where responsibilities encompassed clinical development in regenerative medicine and women's health. Natalie earned a PhD in Biochemistry from UCL and holds a degree in Natural Sciences from the University of Cambridge.